Senseonics Holdings, Inc. · NASDAQ:SENS
Senseonics — Business Update and Analyst Event at ADA 2024
34 slides from Senseonics's conference presentation, June 2024
Slide 1: Eversense CGM System: Business Update and Analyst Event
Eversense ® CGM System The world’s FIRST and ONLY long-term Continuous Glucose Monitoring System Business Update and Analyst Event ADA June 20241
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Any statements in this presentation about future expectations, plans and prospects for Senseonics and its business, including statements regarding managements plans, objectives and goals for future operations, expectations for future financial or other performance, includi
Slide 3: Agenda
Agenda Tim Goodnow, CEO 10:00am Introduction Brian Hansen, President CGM (Ascensia Diabetes Care) 10:05am Commercial strategy Jeff Ruiz, Business Development 10:15am Population health management initiatives Tim Goodnow, CEO 10:25am Innovation Pipeline Rick Sullivan, CFO 10:30am Operations, Financial
Slide 4: Our Mission
OUR MISSION To transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. 4
Slide 5: Corporate Overview and Milestones
CORPORATE OVERVIEW AND MILESTONES The FIRST and ONLY long-term and implantable CGM System. Available by prescription in US and select markets in Europe. Proven technology with rich development history, regulatory approvals and commercial accomplishments. 2016 - 2018 2019 2020 2021 2022 2023 2024 Feb
Slide 6: Significant Unmet Need Among BGM/CGM Users
SIGNIFICANT UNMET NEED AMONG BGM/CGM USERS Why BGM users won't adopt CGM1 Most desired CGM improvements2 Device attached to body Longer Sensor Wear Better Accuracy Cost of CGM Don't feel CGM is necessary 69% 73% 59% Having to insert sensor into own skin Length of time on skin 34% 55% 40% Fit with li
Slide 7: Eversense CGM System addresses unmet needs as the first and only
Eversense CGM System addresses unmet needs as THE FIRST AND ONLY CGM that lasts for 6 months vs. days Fully implantable 3rd generation sensor CGM achieves 8.5% MARD* Transmitter that is removable System with on-body vibe alerts for hypo and hyper warnings System with fresh, gentle-on ski
Slide 8: Commercial Collaboration
COMMERCIAL COLLABORATION Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in BGM ASCENSIA is the Exclusive Worldwide Distribution Partner for Eversense® Senseonics Focus Streamlined Operations on Manufacturing, Research and Development of Next Generati
Slide 9: Commercial Strategy
Commercial Strategy Brian Hansen, President CGM (Ascensia Diabetes Care) 9
Slide 10: Ascensia Diabetes Care Confidential & Proprietary Information. For Display during this Meeting Only. External
Ascensia Diabetes Care Confidential & Proprietary Information. For Display during this Meeting Only. External Disclosure is Strictly 10 Prohibited. © Ascensia Diabetes Care Holdings AG. All rights reserved. PP-SENSGBL-0108
Slide 11: PHC Group's Business
PHC GROUP’S BUSINESS Diabetes Diagnostics & Life Science Healthcare Services Management Diabetes Management with Comprehensive Equipment to Support Healthcare IT Clinical Testing, Blood and Continuous Anatomical Pathology Research in Medical Receipt, Diagnostics/ Reagents, Glucose Monitoring Solutio
Slide 12: A Leader in Glucose Monitoring Systems
GLOBAL DIABETES CARE COMPANY A LEADER in glucose formed 2016 from the sale of Bayer monitoring systems Healthcare, Diabetes Care Business Continuing the heritage of 70+ YEARS of innovative diabetes care products Global sales driven by BGM STRONG PIPELINE of portfolio in over 100 countries innovative
Slide 13: US Commercial Footprint
US COMMERCIAL FOOTPRINT 13
Slide 14: Keys to Success in 2024
KEYS TO SUCCESS IN 2024 HCP Insertion DTC People Market Engagement Network Access Patient Build Brand Renewals 365 Launch Have fun Experience Awareness Readiness 14
Slide 15: Focus on Improving Conversion Funnel
FOCUS ON IMPROVING CONVERSION FUNNEL DTC Conversion Funnel Priority Focus Area Optimize ad creative & targeting to cost-effectively Web Visits drive high quality prospects to website Leads Optimize website to increase lead capture for Submitted qualified, high-scoring prospects Workable Leads Optimi
Slide 16: Ascensia Eversense Creative
ASCENSIA EVERSENSE | RD.3 Creative space150 16 16
Slide 17: Population Health Management Initiatives
Population Health Management Initiatives Jeff Ruiz, Business Development 17
Slide 18: Market Opportunity $413B
MARKET OPPORTUNITY Market Potential $413B • Over 1800 ACO’s Total Cost of • 400 health systems Diabetes In the US • ~500,000 Hyperglycemic and hypoglycemic events annually resulting in hospitalization cost over $25K per event Multiple Potential Revenue Streams Short-term Long-term Expansion Opportun
Slide 19: Under Pressure to Improve Outcomes and Reduce Cost
UNDER PRESSURE TO IMPROVE OUTCOMES AND REDUCE COST Challenges for Health Systems • Increasing healthcare costs • Transition to risk-based reimbursement models • Need for better patient outcomes and cost management Strategic Goals • Enhance patient care quality • Reduce avoidable hospital readmission
Slide 20: Eversense CGM: Uniquely Positioned to Address Health Systems
EVERSENSE CGM: UNIQUELY POSITIONED TO ADDRESS HEALTH SYSTEMS Goals for Eversense® CGM Use Potential Benefits for Health Systems • Long-term implantable CGM system to support • Improved glycemic control over time to stave off patient compliance long-term complications • Reduction in severe hypoglycem
Slide 21: Augmentation by Eversense RPM Services
AUGMENTATION BY EVERSENSE RPMTM SERVICES What is RPM? RPM Objectives • Nurse-based evaluation and • Improved glycemic control monitoring of Eversense CGM • Enhanced patient engagement and adherence to patients treatment plans • Coaching, intervention and • Alerts for more timely interventions improv
Slide 22: Case Study – Mercy Health
CASE STUDY – MERCY HEALTH Mercy Overview Their Strategic Objectives • Operating Revenue: $8 billion • Improve quality and reduce costs of care through • Net Assets: $4.99 billion strategic investments in innovation • Traditional Charity Care: $121 million • Leverage health and economic outcomes to •
Slide 23: Eversense Pipeline
Eversense Pipeline Tim Goodnow, CEO 23
Slide 24: Product Vision
PRODUCT VISION Uniquely differentiated long-term technology solution with multiple product configurations with AID and Smart Pen integration SENSOR All Diabetes Patient Segments NO sensor change for 1 year NO daily calibration required NO transmitter on body For Type 1 and Type 2 Patients On Demand
Slide 25: Portfolio Overview
PORTFOLIO OVERVIEW 2022 2023 2024 2025 Connectivity 180-day Sensor Received iCGM Updates Approval designation BGM Connectivity Direct communication Pivotal Trial Completed iCGM 365-day Sensor Completed 510(k) with Bluetooth data analysis Submitted enabled blood glucose meters Gemini Complete Gemini
Slide 26: Gemini System
GEMINI SYSTEM Autonomous sensor testing with data processing capacity enabling 2 products from 1 platform TECHNOLOGY Enhanced ROME2 sensor with integrated battery; updated algorithm USE CASE Full year use with 1 sensor and 1 cal/week Two unique products: • CGM with • Standalone transmitter therapeut
Slide 27: Freedom System
FREEDOM SYSTEM Elimination of Transmitter by incorporating BLE in the Sensor TECHNOLOGY Enhanced ROME2 sensor with integrated battery and BLE communication; updated algorithm USE CASE Full year use with 1 sensor and 1 cal/week No transmitter included in the System Direct communication between sensor
Slide 28: Operations, Financial Performance & Outlook
Operations, Financial Performance & Outlook Rick Sullivan, CFO 28
Slide 29: Revenue Recognition by Sales Channel
REVENUE RECOGNITION BY SALES CHANNEL Senseonics Ascensia Distributors HCP / Patient 1 Day 0 Day 30/60 Day 60/90 Day 90/120 Senseonics Hospital / HCP Patient 2 CONSIGNMENT / HOSPITAL SYSTEM Day 0 Day 30/60 Projected share of revenue based on existing Collaboration Agreement provisions and current ass
Slide 30: 365-Day Transition: Sensor Shipments
365-DAY TRANSITION Inventory levels will be reset in 4Q with 365-day product Inventory of E3 has been decreasing across the E3 Shipments will various sales channels decrease as a result of the Sensor Shipments anticipated transition to 365-day product Transitioning manufacturing to 365- day product
Slide 31: Senseonics' Global Patient Base
SENSEONICS’ GLOBAL PATIENT BASE 14,000 12,000 10,000 8,000 6,000 4,000 2,000 0 2023 2024 2025 Global Patient Base Poly. (Global Patient Base) 31
Slide 32: Key Financial Targets (Preliminary Projections)
KEY FINANCIAL TARGETS* (PRELIMINARY PROJECTIONS) SENS 2024 SENS Revenue Share % 72.5% 67.5% 2025 & Beyond: Senseonics Revenue $22.0 $24.0 With the 365-day product Gross Margin* being commercialized and 10.0% 15.0% the continued emphasis Operating Expenses on our hospital system $77.5 $82.5 strategy
Slide 33: Appendix A – Key Assumptions for Financial Targets
APENDIX A – KEY ASSUMPTIONS FOR FINANCIAL TARGETS OVERALL Product Approval • Ranges of Financial Targets are based on the current forecasts • Assumed FDA approval of the 365-day product with anticipated growth rate in the US Q3 2024 and launched in Q4 2024. • Revenue for Senseonics is assumed to be
Slide 34: Thank You
THANK YOU 34
Senseonics Holdings — Business Update and Analyst Event at ADA 2024 on 6ix